arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

BRAINSTORM CELL THERAPEUTICS INC.

BCLI
— Price unavailable
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
101 Visible periods
21 Metrics
Peer-ranked Benchmarks
Price Chart
90
Health
Excellent
Bullish
auto_awesome

Analytical Summary

BRAINSTORM CELL THERAPEUTICS INC. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC 24.6% ↗
FCF / Share $-0.08 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity -0.11
info Valuation on last close.

101-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-2.13M
↑ +25.7% —
FCF / Share Free cash flow per share
$-0.08
↑ +80.0% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns ↓
99
Financial Health ↓
100
Cash Quality ↓
47

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 26 years · 101 quarters